About Allievex
Allievex is a company based in Marblehead (United States) founded in 2017. The company has 7 employees as of December 31, 2022. Allievex offers products and services including Tralesinidase Alfa. Allievex operates in a competitive market with competitors including Biogen, Denali Therapeutics, Intra-Cellular Therapies, Ironwood Pharma and Harmony Biosciences, among others.
- Headquarter Marblehead, United States
- Employees 7 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Allievex Corp.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Novo Holdings
& 1 more
-
Employee Count
7
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Allievex
Allievex offers a comprehensive portfolio of products and services, including Tralesinidase Alfa.
Treatment for Sanfilippo Syndrome Type B via targeted administration.
People of Allievex
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Allievex
Investors in Allievex
Allievex has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Novo Holdings and Pappas Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
VC firm focusing on life science sector
|
Locked | Locked | Locked |
Investor details for Allievex
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Allievex
Investment portfolio details for Allievex
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Allievex
Detailed financials for Allievex
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Allievex Comparisons
Peer comparison for Allievex
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Allievex
Allievex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Intra-Cellular Therapies, Ironwood Pharma and Harmony Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for psychiatric and neurologic diseases
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for rare neurological diseases
|
|
| Locked | Locked | Locked |
Small-molecule therapeutics for neurodegenerative diseases are developed.
|
Detailed competitors of Allievex
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Allievex
Complete news archive for Allievex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Allievex
Allievex was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Allievex is headquartered in Marblehead, United States. It is registered at Marblehead, Massachusetts, United States.
As of Dec 31, 2022, the latest employee count at Allievex is 7.
Allievex is a developer of therapeutics for rare pediatric neurodegenerative diseases. The lead compounds tralesinidase alfa for treating Sanfilippo syndrome Type B (Mucopolysaccharidosis IIIB) in children. Tralesinidase alfa is a fusion of recombinant human alpha-N-acetyglucosaminidase (NAGLU) with a peptide derived from insulin-like growth factor 2 (IGF2) used to restore NAGLU activity in the brain.
Allievex's top competitors include Alector, Intra-Cellular Therapies and Entrada Therapeutics.
Allievex offers Tralesinidase Alfa.
Allievex has 2 investors. Key investors include Novo Holdings, and Pappas Capital.